From the publishers of JADPRO

Biomarkers in NSCLC Resource Center

Advertisement

Poziotinib in Previously Treated Patients With NSCLC and HER2 Exon 20 Insertion Mutations

Last Updated: Monday, December 20, 2021

In a cohort of the phase II ZENITH20-2 trial reported in the Journal of Clinical Oncology, Le et al found that the tyrosine kinase inhibitor poziotinib produced responses in previously treated patients with non–small cell lung cancer and HER2 exon 20 insertion mutations.

The ASCO Post
Advertisement
News & Literature Highlights
Advertisement
Advertisement